:

MISTRAL TARGETS €3B RAISE AT €20B VALUATION

AI DESK1 MIN READ
SAT, JUN 13, 2026

■ AI-SUMMARIZED FROM 1 SOURCE ▸ TIMELINE

Mistral AI is reportedly seeking €3 billion in funding that would value the French AI startup at €20 billion, nearly doubling its previous Series C valuation of €11.7 billion.

The funding round would elevate Mistral to unicorn status among European AI companies. At €20 billion (approximately $23.15 billion), the valuation reflects significant investor appetite for European alternatives to US-based AI leaders. Mistral has emerged as a competitive player in the generative AI space with its open-source and commercial language models. The company gained attention for developing models that rival larger competitors while maintaining a lean operational structure. The reported raise would mark a substantial capital injection for the company's continued development and commercialization efforts. Previous funding rounds have backed Mistral's infrastructure investments and model research. This valuation milestone comes amid intensifying competition in the AI sector, with multiple European startups attracting significant venture capital. The funding would position Mistral among the continent's highest-valued AI companies.

■ SOURCES

TechCrunch

■ SUMMARY WRITTEN BY AI FROM THE LINKS ABOVE

■ MORE FROM THE STARTUPS DESK

Colorado-based biotech startup Enveda, which uses AI to discover new drugs from natural sources, secured $311 million in Series E funding at a $2 billion valuation—double its valuation from a year ago.

4H AGOAI Desk

Modal Labs and Baseten, two platforms enabling businesses to run AI models, are in advanced funding talks that would significantly boost their valuations. The rounds reflect growing investor appetite for AI infrastructure services.

6H AGOAI Desk

Ema, an AI agent platform automating corporate processes in HR, IT, and finance, secured $77 million in Series B funding led by Creaegis. The round brings the startup's total funding to $140 million.

8H AGOAI Desk

Enveda Therapeutics raised $311 million in funding, bringing the AI biotech company's valuation to $2 billion. The capital will accelerate clinical trials for drugs derived from natural compounds.

9H AGOAI Desk

■ SUBSCRIBE TO THE DAILY BRIEF

ONE EMAIL, 5 STORIES, 06:00 UTC. UNSUBSCRIBE ANYTIME.